GPC Biotech Merger With Agennix May Have A Billionaire’s Reasons For Success

Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.